Quidel Q4 Revenues Shrink 7 Percent on Softer Flu Business; MDx Projects Remain on Track | GenomeWeb

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Tuesday that its fourth quarter revenues declined 7 percent year over year on slower influenza and respiratory disease business.

The San Diego-based diagnostics company saw its revenues during the three months ended Dec. 31, 2013 retreat to $50.2 million from $53.9 million in the year-ago period, but still beat the consensus analyst estimate of $48.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.